Herbs (Global Traditional) · African
Sceletium tortuosum
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Sceletium tortuosum is a South African succulent containing mesembrine alkaloids that modulate serotonin reuptake and PDE4 activity. The plant demonstrates clinically-supported anxiolytic and mood-enhancing effects through dual-action on serotonergic pathways.
Sceletium tortuosum is a succulent plant native to South Africa, traditionally known as Kanna, belonging to the Aizoaceae family. The leaves and stems are processed into standardized extracts like Zembrin® through a 2:1 extraction method, yielding mesembrine-type alkaloids as the primary active compounds.
Clinical evidence consists of small randomized controlled trials in healthy volunteers only, with no studies in clinical populations with diagnosed anxiety or depression. Key trials include a 3-month safety study (n=37, PMID: 23441963), acute stress response studies (n=20, PMID: 32761980), and a 3-week neurocognitive trial (n=21, PMID: 25389443).
Clinically studied doses use Zembrin® standardized extract (2% total alkaloids, 0.4% mesembrine): 8-25 mg once daily for up to 3 months. Acute anxiety effects studied at 25 mg single dose. No studies on raw powder or traditional fermented forms. Consult a healthcare provider before starting any new supplement.
Sceletium tortuosum is not consumed as a food for macronutrient value; it is a succulent plant used as a psychoactive botanical preparation. Its relevance is entirely in its bioactive alkaloid profile rather than conventional nutritional content (negligible protein, fat, carbohydrate, and fiber contribution at typical doses of 25–50 mg standardized extract or 50–200 mg raw plant material). **Key bioactive compounds:** • **Mesembrine** (primary alkaloid, ~0.3–1.3% of dry plant weight depending on fermentation/preparation): Selective serotonin reuptake inhibitor (SRI) and potent phosphodiesterase-4 (PDE4) inhibitor; considered the principal anxiolytic and mood-enhancing constituent. Bioavailability is enhanced by traditional fermentation ('kougoed' process), which converts less active alkaloids into mesembrine-type compounds. • **Mesembrenone** (~0.1–0.5% dry weight): Dual SRI and PDE4 inhibitor; contributes to serotonergic activity; relative proportion increases in unfermented material. • **Mesembrenol** (trace to ~0.2%): Minor alkaloid with weaker SRI activity. • **Mesembranol** (trace to ~0.2%): Minor alkaloid contributing to overall pharmacological profile. • **Δ7-Mesembrenone** (variable trace amounts): Present in some chemotypes; biological activity less characterized. • **Total mesembrine-type alkaloids** in standardized commercial extracts (e.g., Zembrin®): Typically standardized to ≥0.35–0.40% total alkaloids, with defined ratios of mesembrine, mesembrenone, mesembrenol, and mesembranol. • **Other constituents:** Trace amounts of oxalic acid, flavonoids, and tannins are present in crude plant material but are not considered pharmacologically relevant at typical doses. **Mineral/vitamin content:** Not nutritionally significant at therapeutic doses (25–50 mg extract); no meaningful contribution of vitamins or minerals. **Bioavailability notes:** Oral bioavailability of mesembrine alkaloids appears adequate based on clinical efficacy at low doses (25 mg Zembrin® extract). Traditional fermentation (anaerobic curing for 2–8 days) significantly alters alkaloid ratios, increasing mesembrine relative to mesembrenone, and is believed to improve tolerability and potency. The alkaloids are lipophilic and likely undergo hepatic first-pass metabolism; sublingual or insufflation routes used traditionally may bypass first-pass effects and increase bioavailability, though clinical data is limited to oral dosing.
Mesembrine, the primary alkaloid, acts as a selective serotonin reuptake inhibitor (SSRI) and phosphodiesterase-4 (PDE4) inhibitor. This dual mechanism increases synaptic serotonin availability while reducing inflammatory cytokine production. The PDE4 inhibition also elevates cAMP levels, contributing to improved stress resilience and mood regulation.
A controlled trial with 20 participants demonstrated significant reductions in subjective anxiety scores and heart rate variability during stress tasks after acute dosing. A 3-month safety study involving 37 subjects reported improvements in perceived stress management and sleep quality scores. Current evidence is preliminary but promising, with most studies involving small sample sizes and short durations. Larger, long-term randomized controlled trials are needed to establish therapeutic efficacy.
Common side effects include mild headache, nausea, and drowsiness at higher doses. Potential interactions exist with antidepressants, particularly SSRIs and MAOIs, due to mesembrine's serotonergic activity. Contraindicated in individuals with bipolar disorder or those taking psychiatric medications without medical supervision. Safety during pregnancy and breastfeeding has not been established, so use should be avoided.
